Compare Ascendis Pharma A/S (ASND) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.74. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ASND | YMAG | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $277.18 | $15.98 |
52-Week Low | $163.32 | $11.00 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
YMAG trades at $11.81 with a 1.2% daily gain, showing modest momentum amid bearish technical signals. The ETF's weekly dividend strategy provides income but faces headwinds from its overall bearish technical rating and mixed oscillators. Recent news highlights YieldMax's consistent distribution announcements, though analyst coverage remains limited for this specialized fund-of-ETFs product.
The outlook remains cautious given the bearish technical setup and structural concerns about NAV decay in option-income strategies. While weekly distributions offer income appeal, the fund's performance depends heavily on volatility monetization capabilities during rangebound markets. Key risks include expense ratio drag and underperformance during strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
